Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma | MicrobiomeTrials← Back to trialsNCT07724457
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2026-08-14Est. Completion: 2033-11-01
Enrollment target: 271 participants Other microbiome trials you might be interested in
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating p…
Birmingham, United StatesEst. completion Feb 1, 2027
Acute Lymphoblastic LeukemiaB Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Recurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, predni…
Birmingham, United StatesEst. completion Jun 1, 2022